Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerSuzanne L. Topalian, Mario Sznol, F. Stephen Hodi et al.|New England Journal of Medicine|2012Cited by 12.6k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerScott Gettinger, Julie R. Brahmer, Leora Horn et al.|Journal of Clinical Oncology|2015Cited by 1.2k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020David S. Ettinger, Mark Hennon, Leora Horn et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 1k
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)Leora Horn, Wilfried Eberhardt|Journal of Clinical Oncology|2017Cited by 872
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018David S. Ettinger, Miranda Hughes, Dara L. Aisner et al.|Journal of the National Comprehensive Cancer Network|2018Cited by 471